merck & co. - Search News

Merck, Keytruda

New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling a new version of its drug Keytruda.

Reuters on MSN · 20h

New version of Merck's Keytruda faces possible patent battle, WSJ reports

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.

BioSpace · 21h

Merck’s Injectable Keytruda Plans Create Legal Dispute With Halozyme: WSJ

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that convert intravenous drugs into injectable versions.

Seeking Alpha on MSN · 1d

Merck set for patent battle with Halozyme over injectable Keytruda: WSJ

A new patent dispute is brewing between Halozyme Therapeutics (NASDAQ:HALO), a biotech focused on drug delivery technology, and Merck (NYSE:MRK) over an injectable version of the New Jersey-based pharma giant’s cancer blockbuster,

16hon MSN

Merck & Co. (MRK): An Undervalued Wide Moat Stock to Buy According to Analysts

We recently compiled a list of the 12 Undervalued Wide Moat Stocks to Buy According to Analysts. In this article, we are ...

3MRK : Spotlight on Merck & Co: Analyzing the Surge in Options Activity

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Merck & Co. Inc. stock outperforms competitors on strong trading day

Merck & Co. Inc. closed 32.72% below its 52-week high of $134.63, which the company achieved on June 25th.

Delaware approves $30.2 million taxpayer-funded grant for Merck to build in state

The state of Delaware has offered Merck a $30.2 million grant to encourage the company to choose the Wilmington-area location. If Merck accepts the grant, the company would be required to create 375 ...

MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!

NEW YORK CITY, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Merck & Co.'s Real Value: A Deep Dive Into Its Fundamentals

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

Fierce Biotech2h

Merck KGaA fails midphase lupus trial, says totality of data support further development

One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. | One of Merck KGaA’s leading immunology ...

TOP RANKED ROSEN LAW FIRM Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK

Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class ...

Merck expects cancer therapy Keytruda to be part of government price setting in 2026

Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...

Nordot on MSN3h

Merck sees slight earnings, sales growth in 2025

German science and technology company Merck on Thursday forecast its net sales to be in the range of €21.5 billion ($23.2 ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Merck, Keytruda

Related topics